A Study Of PF-05175157 In Healthy Volunteers
NCT01274663 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 63
Last updated 2011-10-12
Summary
The primary purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of single oral doses of PF-05175157 in healthy volunteers.
Conditions
- Diabetes Mellitus, Type 2
Interventions
- DRUG
-
PF-05175157 or Placebo
One dose of PF-05175157 will be administered as a powder-in-capsule in the fasting state in the AM; correspondingly, one dose of a matched powder-in-capsule placebo will be administered in the fasting state in the AM.
- DRUG
-
PF-05175157 or Placebo
One dose of PF-05175157 will be administered as a powder-in-capsule in the fasting state in the AM; correspondingly, one dose of a matched powder-in-capsule placebo will be administered in the fasting state in the AM.
- DRUG
-
PF-05175157 or Placebo
One dose of PF-05175157 will be administered as a powder-in-capsule in the fasting state in the AM; correspondingly, one dose of a matched powder-in-capsule placebo will be administered in the fasting state in the AM.
- DRUG
-
PF-05175157 or Placebo
One dose of PF-05175157 will be administered as a powder-in-capsule in the fasting state in the AM; correspondingly, one dose of a matched powder-in-capsule placebo will be administered in the fasting state in the AM.
- DRUG
-
PF-05175157 or Placebo
One dose of PF-05175157 will be administered as a powder-in-capsule in the fasting state in the AM; correspondingly, one dose of a matched powder-in-capsule placebo will be administered in the fasting state in the AM.
- DRUG
-
PF-05175157 or Placebo
One dose of PF-05175157 will be administered as a powder-in-capsule in the fasting state in the AM; correspondingly, one dose of a matched powder-in-capsule placebo will be administered in the fasting state in the AM.
- DRUG
-
PF-05175157 or Placebo
One dose of PF-05175157 will be administered as a powder-in-capsule immediately after breakfast; correspondingly, one dose of a matched powder-in-capsule placebo will be administered immediately after breakfast.
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Pfizer CT.gov Call Center · Pfizer
Study Design
- Allocation
- RANDOMIZED
- Purpose
- BASIC_SCIENCE
- Masking
- DOUBLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 45 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2010-11-30
- Primary Completion
- 2011-05-31
- Completion
- 2011-05-31
Countries
- United States
Study Locations
More Related Trials
-
A Study To Estimate The Effect Of Repeated Dosing of PF-05175157 On The Pharmacokinetics Of A Single Dose Of Simvastatin In Healthy Adult Subjects
NCT01469468 ·Status: COMPLETED ·Phase: PHASE1
-
Single Dose Study of PF-05230907 in Healthy Japanese Subjects
NCT02537002 ·Status: COMPLETED ·Phase: PHASE1
-
A Study In Healthy People To Evaluate Safety, Toleration, Pharmacokinetics And Pharmacodynamics Of Multiple Oral Doses Of PF-06743649
NCT02151617 ·Status: COMPLETED ·Phase: PHASE1
-
Evaluation Of Safety, Tolerability And Pharmacokinetics Of Single And Multiple Doses Of Compound PF-06823859
NCT02766621 ·Status: COMPLETED ·Phase: PHASE1
-
A Study Of Three PF-05190457 Formulations In Healthy Volunteers
NCT01522807 ·Status: COMPLETED ·Phase: PHASE1
-
A First-In-Human Study of the Study Medicine, Called PF-07291177, in Healthy Adult Participants
NCT05434091 ·Status: WITHDRAWN ·Phase: PHASE1
-
First In Human, Single Escalating Oral Dose Study Of PF-06882961 In Healthy Adult Subjects
NCT03309241 ·Status: COMPLETED ·Phase: PHASE1
-
Study to Evaluate Safety and Tolerability of Single Ascending Doses of Multiple Formulations of PF-06650833 in Healthy Subjects Under Fasted and Fed Conditions
NCT02224651 ·Status: COMPLETED ·Phase: PHASE1
-
A Study In Japanese Healthy Male Volunteers To Investigate The Safety, Tolerability And Pharmacokinetics Of PF-02341066
NCT01250730 ·Status: COMPLETED ·Phase: PHASE1
-
Single Dose of PF-06835919 Escalation Study in Healthy Adult Subjects
NCT02974374 ·Status: COMPLETED ·Phase: PHASE1
-
A Single Dose Study Of PF-04620110 In Healthy Subjects
NCT01166217 ·Status: COMPLETED ·Phase: PHASE1
-
A Study To Observe Safety And Blood Concentrations Of PF-06649751 During And Following The Oral Administration Of Multiple Doses Of PF-06649751 In Healthy Adult Western and Japanese Volunteers
NCT02066909 ·Status: COMPLETED ·Phase: PHASE1
-
Multiple Dose Safety Toelrability, Pharmacokinetics and Midazolam Interaction In Healthy Overweight And Obese Subjects
NCT01757756 ·Status: COMPLETED ·Phase: PHASE1
-
A Multiple Dose Study Of PF-04620110 In Healthy Overweight Or Obese Subjects
NCT01146327 ·Status: COMPLETED ·Phase: PHASE1
-
Single Dose, Dose Escalation Healthy Volunteers Study Of PF-05105679
NCT01393652 ·Status: COMPLETED ·Phase: PHASE1
-
Single Dose Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study Of PF-06291874 In Healthy Adult Subjects
NCT01794364 ·Status: COMPLETED ·Phase: PHASE1
-
Study To Evaluate The Safety, Tolerability, And Pharmacokinetics Of Oral Pf-06650833 In Healthy Subjects
NCT02485769 ·Status: COMPLETED ·Phase: PHASE1
-
First In Human Study Of Increasing Oral Doses Of PF-04634817
NCT01098877 ·Status: COMPLETED ·Phase: PHASE1
-
A Phase 1 Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-05230907 In Healthy Volunteers
NCT01897142 ·Status: COMPLETED ·Phase: PHASE1
-
A Study To Evaluate The Safety, Tolerability And Plasma Drug Levels Following A Single Dose Of PF-04995274 In Healthy Adult Volunteers
NCT01091272 ·Status: COMPLETED ·Phase: PHASE1
-
A Study In Healthy People To Evaluate Safety, Toleration And Time Course Of Plasma Concentration Of Multiple Oral Doses Of PF-04895162
NCT01691274 ·Status: COMPLETED ·Phase: PHASE1
-
Safety and Pharmacokinetics of Single Intravenous Doses of Peginesatide in Healthy Volunteers
NCT00097747 ·Status: COMPLETED ·Phase: PHASE1
-
Single Dose Study to Assess the Safety, Tolerability and Pharmacokinetics(PK) of PF-06865571
NCT03092232 ·Status: COMPLETED ·Phase: PHASE1
-
A Single Ascending Dose Study To Evaluate Safety And Pharmacokinetics Of Compound PF-06648671 In Healthy Subjects
NCT02316756 ·Status: COMPLETED ·Phase: PHASE1
-
Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Intravenous and Multiple Subcutaneous and Intravenous Doses of PF-06480605 in Healthy Subjects.
NCT01989143 ·Status: COMPLETED ·Phase: PHASE1